Older E-Patients Prefer Facts, Not Friendship from Health Organizations Communicating Via Social Media, According to Path of the Blue Eye Project Survey Study reveals older e-patients want useful medical news and information, not friendly one-on-one conversation. (PRWeb Nov 19, 2009)
Read the full story at http://www.prweb.com/releases/epatientstudy/09/prweb3229054.htm
Source: www.prweb.comAdamas Pharmaceuticals Expands Clinical Study For Triple-Combination Antiviral Drug Therapy In Immune Compromised Patients Adamas Pharmaceuticals, Inc., a privately held company, announced that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe.
Source: www.medicalnewstoday.comProfiles International Releases Executive’s Guide to Employee Assessments Profiles International has released their latest report “The Executive’s Guide to Employee Assessments.” This new report outlines the different types of assessments available to executives, ways to use such assessments, and keys to selecting the right assessments for the executive’s needs. (PRWeb Nov 19, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3230614.htm
Source: www.prweb.comPlastic Surgeons Respond To Proposed Cosmetic Surgery Tax Surprise Addition to Healthcare Bill is Arbitrary, Difficult to Administer (PRWeb Nov 20, 2009)
Read the full story at http://www.prweb.com/releases/plastic_surgeons/healthcare_bill/prweb3237974.htm
Source: www.prweb.comInnovative Therapy That Offers New Hope For Borderline Personality Disorder Patients coping with the chaos and misery of Borderline Personality Disorder now have reason for strong confidence in making major life changes through a new treatment, Schema Therapy. For the first time, three major outcome studies have shown that many patients with Borderline Personality Disorder can achieve full recovery across the complete range of symptoms.
Source: www.medicalnewstoday.comMillennium Initiates First Clinical Trial With The First Oral Proteasome Inhibitor Millennium: The Takeda Oncology Company announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company's second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. MLN9708 is the third molecule Millennium has developed from its innovative research in protein homeostasis.
Source: www.medicalnewstoday.comDietary Supplements Sold on Internet by Bodybuilding.com Dietary
supplements recalled due to undeclared steroids in products with risk of acute liver injury.
Source: www.fda.govRSA Corp Shares Business, IT and Hiring Advice on New Radio Segment Business technology services firm announced a weekly radio segment on staffing trends and how IT can drive operational optimization and boost efficiencies. New show streams live Wednesdays at 3 p.m. on www.cnn650.com. (PRWeb Nov 19, 2009)
Read the full story at http://www.prweb.com/releases/businesstechnology/houstonradio/prweb3223964.htm
Source: www.prweb.comMedical Resources Staffing Services Partners with Local Healthcare Organization for H1N1 Virus Vaccination Medical staffing company provides temporary workers for large-scale health initiative. (PRWeb Nov 19, 2009)
Read the full story at http://www.prweb.com/releases/2009/11/prweb3230804.htm
Source: www.prweb.comClinical Data, Inc. Initiates Phase III Trial Of Stedivaze For Cardiac Stress Testing Clinical Data, Inc. (NASDAQ: CLDA) announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart.
Source: www.medicalnewstoday.com
# posted by Network @ 4:14 PM
